Claimed effect · LL-37

Does LL-37 help with systemic 'immune support' or anti-inflammatory use?

D
Grade D — no human evidence0 · effect size: not measurable
Short answerNo human evidence. As of 3 September 2026, only 0 exists for LL-37 for systemic 'immune support' or anti-inflammatory use. No human data by injection at all. In cells and mice LL-37 is a driver of inflammation in psoriasis and lupus, which argues against, not for, the marketed use.

What the studies show

No human data by injection at all. In cells and mice LL-37 is a driver of inflammation in psoriasis and lupus, which argues against, not for, the marketed use.

Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.

  1. 1
    Reviews of LL-37 biology in infection, wound repair and autoimmunity.VariousPreclinical mechanism; no systemic human data.

In context

LL-37 is the only cathelicidin peptide humans make — a 37-amino-acid antimicrobial produced by skin, gut and immune cells that kills bacteria and signals inflammation and repair. The human evidence is two randomised trials of a topical gel on venous leg ulcers: a 34-patient phase 2a that found faster healing, and a 148-patient phase 2b that did not, except in a subgroup of large wounds. Nothing supports the injected 'immune' or 'anti-inflammatory' uses sold online, and injected LL-37 is pro-inflammatory in the laboratory.

LL-37 is not approved. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is LL-37 proven to help with systemic 'immune support' or anti-inflammatory use?
No. There is no human evidence for it (0); the claim rests on animal or cell studies and LYO grades it D.
What studies are behind the grade?
No human data by injection at all. In cells and mice LL-37 is a driver of inflammation in psoriasis and lupus, which argues against, not for, the marketed use.
Is LL-37 approved for this?
No. LL-37 is not approved; it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for LL-37

Reviewed 3 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →